Gain Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Gain Therapeutics
GANX Stock  USD 1.99  0.18  9.94%   
Gain Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Gain Therapeutics' valuation are provided below:
Gross Profit
-8.9 M
Market Capitalization
69.6 M
Enterprise Value Revenue
138.3348
Earnings Share
(0.61)
Quarterly Revenue Growth
(1.00)
We have found one hundred twenty available fundamental trends for Gain Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Gain Therapeutics regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 74.9 M in 2026. Enterprise Value is likely to rise to about 64.4 M in 2026

Gain Therapeutics Total Revenue

0.0

Check Gain Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Gain Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 648.2 K, Net Interest Income of 431.2 K or Depreciation And Amortization of 101.5 K, as well as many indicators such as Price To Sales Ratio of 842, Dividend Yield of 0.0 or PTB Ratio of 6.36. Gain financial statements analysis is a perfect complement when working with Gain Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Gain Stock
Check out the analysis of Gain Therapeutics Correlation against competitors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Gain Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets16.5 M13.9 M8.3 M
Slightly volatile
Short and Long Term Debt Total837.8 K587.7 K1.1 M
Slightly volatile
Other Current Liabilities1.5 M2.8 M945.2 K
Slightly volatile
Total Current Liabilities3 M4.5 M1.8 M
Slightly volatile
Other Liabilities179.3 K181.2 K99 K
Slightly volatile
Property Plant And Equipment Net596.8 K371.8 K424.3 K
Slightly volatile
Accounts Payable898.4 K1.1 M523.4 K
Slightly volatile
Cash11.7 M11.9 M6 M
Slightly volatile
Non Current Assets Total1.1 M599.6 K648.6 K
Slightly volatile
Non Currrent Assets Other46.1 K36.9 K27.4 K
Slightly volatile
Other Assets41.4 K55.6 K27.7 K
Slightly volatile
Cash And Short Term Investments14.5 M11.9 M7.2 M
Slightly volatile
Net Receivables924.7 K880.6 K208.4 K
Slightly volatile
Common Stock Shares Outstanding13.2 M26.3 M10 M
Slightly volatile
Liabilities And Stockholders Equity16.5 M13.9 M8.3 M
Slightly volatile
Non Current Liabilities Total1.2 M1 M1.1 M
Pretty Stable
Other Current Assets678.4 K518.5 K368.6 K
Slightly volatile
Other Stockholder Equity107.2 M102.1 M29.6 M
Slightly volatile
Total Liabilities4.2 M5.5 M3 M
Slightly volatile
Total Current Assets15.4 M13.3 M7.7 M
Slightly volatile
Short Term Debt255.3 K311.8 K174.9 K
Slightly volatile
Common Stock3.3 K3.1 K924
Slightly volatile
Property Plant Equipment157.7 K166 K311.1 K
Pretty Stable
Current Deferred Revenue422.5 K290 K372.7 K
Very volatile
Common Stock Total Equity1.4 K1.4 K601
Slightly volatile
Capital Lease Obligations183.4 K193.1 K304 K
Slightly volatile
Inventory1.6 M1.6 M606 K
Slightly volatile
Property Plant And Equipment Gross679.8 K513.7 K404.5 K
Slightly volatile
Capital Stock3.3 K3.1 K1 K
Slightly volatile
Non Current Liabilities Other723.7 K689.3 K262.7 K
Slightly volatile
Long Term Debt412.6 K295.5 K614.3 K
Slightly volatile
Short and Long Term Debt102 K126.7 K54 K
Slightly volatile
Intangible Assets148.8 K120.8 K190.7 K
Slightly volatile
Long Term Debt Total396.2 K445.7 K486.5 K
Slightly volatile
Capital Surpluse45.9 M51.6 M56.3 M
Slightly volatile

Gain Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision648.2 K617.3 K126 K
Slightly volatile
Depreciation And Amortization101.5 K96.7 K25.1 K
Slightly volatile
Interest Expense298.7 K284.5 K125 K
Slightly volatile
Selling General Administrative6.1 M11 M3.4 M
Slightly volatile
Other Operating Expenses12.8 M23.4 M7.4 M
Slightly volatile
Research Development6.7 M12.4 M4 M
Slightly volatile
Total Operating Expenses24.6 M23.4 M7.2 M
Slightly volatile
Reconciled Depreciation101.5 K96.7 K27 K
Slightly volatile
Income Tax Expense648.2 K617.3 K122.3 K
Slightly volatile
Cost Of Revenue71.9 K75.7 K2.4 M
Pretty Stable
Selling And Marketing Expenses49.7 K52.3 K33.4 K
Slightly volatile
Interest Income327.1 K321.4 K375.3 K
Very volatile

Gain Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.1 M13.6 M5.3 M
Slightly volatile
Depreciation101.5 K96.7 K27.3 K
Slightly volatile
Capital Expenditures46.1 K25.9 K25.3 K
Slightly volatile
End Period Cash Flow11.7 M12 M6 M
Slightly volatile
Cash Flows Other Operating1.2 M1.4 M1.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio8428872.3 K
Slightly volatile
Days Sales Outstanding1.5 K1.4 K651
Slightly volatile
Average Payables777 K1.3 M767 K
Slightly volatile
Stock Based Compensation To Revenue55.8153.1616.2331
Slightly volatile
Capex To Depreciation0.290.316.6768
Slightly volatile
EV To Sales6296622.3 K
Slightly volatile
Payables Turnover9.825.8310.838
Slightly volatile
Sales General And Administrative To Revenue18517660.4439
Slightly volatile
Research And Ddevelopement To Revenue19718882.3027
Slightly volatile
Capex To Revenue0.440.250.4346
Pretty Stable
Cash Per Share0.390.410.5382
Slightly volatile
Days Payables Outstanding40.2264.839.0406
Slightly volatile
Income Quality0.680.830.7545
Slightly volatile
Intangibles To Total Assets0.00710.010.0065
Slightly volatile
Current Ratio3.662.672.6982
Slightly volatile
Receivables Turnover0.250.260.9118
Pretty Stable
Capex Per Share8.0E-49.0E-40.0023
Pretty Stable
Average Receivables141.4 K134.7 K66.2 K
Slightly volatile
Revenue Per Share0.00530.00380.0048
Slightly volatile
Interest Debt Per Share0.03120.03280.1562
Slightly volatile
Debt To Assets0.05880.06190.8961
Slightly volatile
Operating Cycle1.5 K1.4 K651
Slightly volatile
Days Of Payables Outstanding40.2264.839.0406
Slightly volatile
Ebt Per Ebit1.111.121.05
Pretty Stable
Long Term Debt To Capitalization0.04680.04929.5576
Slightly volatile
Quick Ratio3.662.672.6982
Slightly volatile
Net Income Per E B T0.810.920.9913
Slightly volatile
Cash Ratio2.962.392.1936
Slightly volatile
Cash Conversion Cycle1.5 K1.4 K645
Slightly volatile
Days Of Sales Outstanding1.5 K1.4 K651
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0228
Slightly volatile
Fixed Asset Turnover0.0960.08490.0891
Slightly volatile
Debt Ratio0.05880.06190.8961
Slightly volatile
Price Sales Ratio8428872.3 K
Slightly volatile
Asset Turnover0.00320.00340.0186
Slightly volatile

Gain Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap74.9 M56.8 M66.7 M
Pretty Stable
Enterprise Value64.4 M45.6 M61.9 M
Slightly volatile

Gain Fundamental Market Drivers

Gain Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Gain Therapeutics Financial Statements

Gain Therapeutics investors use historical fundamental indicators, such as Gain Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Gain Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue290 K422.5 K
Cost Of Revenue75.7 K71.9 K
Stock Based Compensation To Revenue 53.16  55.81 
Sales General And Administrative To Revenue 175.95  184.75 
Research And Ddevelopement To Revenue 187.90  197.30 
Capex To Revenue 0.25  0.44 
Revenue Per Share 0.00  0.01 
Ebit Per Revenue(463.77)(440.59)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY